Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             288 results found
no title author magazine year volume issue page(s) type
1 Author index 1996
 32 S2 p. 61-66
6 p.
 article
2 DI-1. Chemotherapy: Is more better? DI-1-2 No Hortobagyi, Gabriel N.
 1996
 32 S2 p. 1-
1 p.
 article
3 DI-1. Chemotherapy: Is more better? DI-1-1 Yes Antman, Karen H.
 1996
 32 S2 p. 1-
1 p.
 article
4 DI-3. Has primary chemotherapy a routine role? DI-3-2 No Van de Velde, C.J.H.
 1996
 32 S2 p. 2-
1 p.
 article
5 DI-3. Has primary chemotherapy a routine role? DI-3-1 Yes Bonadonna, G.
 1996
 32 S2 p. 1-2
2 p.
 article
6 DI-2. Screening, Yes or No? DI-2-2 No Baines, C.J.
 1996
 32 S2 p. 1-
1 p.
 article
7 DI-2. Screening, Yes or No? DI-2-1 Yes Ciatto, S.
 1996
 32 S2 p. 1-
1 p.
 article
8 Does Semi-Quantitative Evaluation Improve the Prognostic Value of Histological Grade in Breast Carcinoma: Comparison of Scarff-Bloom-Richardson (SBR) and Elston-Ellis (EE) Grading Systems in a Series of 825 Cases with a Follow-Up of 10 Years Zafrani, B.
 1996
 32 S2 p. 39-
1 p.
 article
9 EP-1 breast cancer imaging Dilhuydy, M.H.
 1996
 32 S2 p. 5-
1 p.
 article
10 EP-3 Follow-up after primary treatment del Turco, M.Rosselli
 1996
 32 S2 p. 5-
1 p.
 article
11 EP-4 Surveillance of Patient with Metastatic Disease Paridaens, R.
 1996
 32 S2 p. 5-
1 p.
 article
12 EP-2 What the non-surgeons have to know about surgery? Mansel, R.-E.
 1996
 32 S2 p. 5-
1 p.
 article
13 Metastases: A new diagnostic method Bonnema, J.
 1996
 32 S2 p. 28-
1 p.
 article
14 PL-1 Genetic predtsposition to breast cancer Ponder, B.A.J.
 1996
 32 S2 p. 3-
1 p.
 article
15 PL-3 prognostic factors in treatment planning: Use or abuse? Bonichon, F.
 1996
 32 S2 p. 3-
1 p.
 article
16 PL-2 Selective control of oncogene expression in tumors. Therapeutical developments Hélène, C.
 1996
 32 S2 p. 3-
1 p.
 article
17 PP-1-7 Accumulation of TP53 as predictor of response to chemotherapy of recurrent breast cancer Berns, P.M.J.J.
 1996
 32 S2 p. 11-
1 p.
 article
18 PP-3-9 Acute toxicities of concurrent chemotherapy (CT) & reduced-dose radiotherapy (RT) for patients treated with breast-conserving surgery Recht, A.
 1996
 32 S2 p. 22-
1 p.
 article
19 PP-5-18 adjuvant epirublcin and CMF +/− hormonotherapy in more than 3 nodes positive breast cancer patients: preliminary data de Matteis, A.
 1996
 32 S2 p. 37-38
2 p.
 article
20 PP-9-15 Analysis of angiogenesis, PCNA, c-er b B-2, and p53 associated with long-term survival in japanese women with breast cancer Kato, T.
 1996
 32 S2 p. 57-58
2 p.
 article
21 PP-8-27 Analysis of factors that improve quality-of-life of patients with advanced or recurrent breast cancer Shimozuma, K.
 1996
 32 S2 p. 53-
1 p.
 article
22 PP-3-12 Angiosarcomas of the breast after radiation for carcinoma: 3 new cases from Institut G Roussy Molitor, J.L.
 1996
 32 S2 p. 22-
1 p.
 article
23 PP-8-4 An open, comparative randomized trial comparing formestane vs oral megestrol acetate as a second-line therapy in postmenopausal advanced breast cancer patients Rose, C.
 1996
 32 S2 p. 49-
1 p.
 article
24 PP-7-10 A phase II trial on high dose (240 MG) toremifene in the treatment of advanced breast cancer Baltina, D.
 1996
 32 S2 p. 47-
1 p.
 article
25 PP-1-16 Apoptosis-loss and expression of death-related genes in breast carcinomas Sierra, A.
 1996
 32 S2 p. 12-13
2 p.
 article
26 PP-2-2 A prognostic index for breast ductal carcinoma in situ (DCIS) Silverstein, M.J.
 1996
 32 S2 p. 14-15
2 p.
 article
27 PP-2-11 a prospective randomized trial of short versus long hospital stay after surgery for breast cancer Bonnema, J.
 1996
 32 S2 p. 16-
1 p.
 article
28 PP-8-5 A randomised study assessing oestrogen suppression with arimidex™ (Anastrozole) and formestane in postmenopausal advanced breast cancer (ABC) patients Dowsett, M.
 1996
 32 S2 p. 49-50
2 p.
 article
29 PP-6-24 A Retrospective Analysis of 124 Cases on the Different Clinical Outcome for Patients with ER−/PR+ Breast Tumors as Compared with ER−/PR− Roy, J.A.
 1996
 32 S2 p. 42-
1 p.
 article
30 PP-8-7 Assessment of response in bone within an EORTC randomised trial of bisphosphonate treatment (10924) Vinholes, J.
 1996
 32 S2 p. 50-
1 p.
 article
31 PP-5-16 A Study of Postoperative Adjuvant Chemotherapy of 5′-DFUR in Breast Cancer Patients (1st Report) — On Compliance and Safety — “The 5′-BC Study Group” (5′-DFUR Adjuvant Chemotherapy for Breast Cancer Study Group) Koyama, H.
 1996
 32 S2 p. 37-
1 p.
 article
32 PP-5-8 Atlas: An international megatrial of tamoxifen duration Davies, Christina
 1996
 32 S2 p. 36-
1 p.
 article
33 PP-6-7 Automated grading in a prognostic index Kohlhardt, S.R.
 1996
 32 S2 p. 39-
1 p.
 article
34 PP-3-19 axil 95 Avril, A.
 1996
 32 S2 p. 24-
1 p.
 article
35 PP-2-25 Axillary clearance without drainage in breast cancer Stöckle, E.
 1996
 32 S2 p. 19-
1 p.
 article
36 PP-2-29 Axillary dissection for breast cancer: Long-term functional results Tribondeau, P.
 1996
 32 S2 p. 20-
1 p.
 article
37 PP-2-12 Axillary lymphadenectomy by lipolysis and liposuction: A pilot study Brun, J.L.
 1996
 32 S2 p. 16-
1 p.
 article
38 PP-2-8 Axillary lymphadenectomy prepared by fat aspiration versus functional axillary lymphadenectomy (fal): Preliminary results of a prospective randomized trial Giard, S.
 1996
 32 S2 p. 16-
1 p.
 article
39 PP-2-26 Axillary lymphadenectomy without drainage Garbay, J.R.
 1996
 32 S2 p. 19-
1 p.
 article
40 PP-2-19 Axillary lymph node dissection for non-palpable breast cancer — 314 cases Le Bouědec, G.
 1996
 32 S2 p. 18-
1 p.
 article
41 PP-4-34 Axillary lymph nodes in breast cancer: Assessment with ‘power’ doppler ultrasound Brightmore, T.G.J.
 1996
 32 S2 p. 32-33
2 p.
 article
42 PP-8-17 Biochemical markers of bone resorption predict response to bisphosphonate treatment Vinholes, I.
 1996
 32 S2 p. 51-52
2 p.
 article
43 PP-4-39 Body image after breast cancer: Results from a patient derived measure Baxter, N.
 1996
 32 S2 p. 33-34
2 p.
 article
44 PP-4-15 BRCA1 Gene alterations in sporadic breast cancer Gomendio, B.
 1996
 32 S2 p. 29-
1 p.
 article
45 PP-4-9 Breast cancer and in vitro fertilization Jourdain, O.
 1996
 32 S2 p. 28-
1 p.
 article
46 PP-4-30 Breast cancer: A retrospective study of two ethnic groups in the center of Israel Ben-Aharon, U.
 1996
 32 S2 p. 32-
1 p.
 article
47 PP-8-26 Breast cancer bone metastases specifically express parathyroid hormone related protein (PTHrP) and its receptor Downey, S.E.
 1996
 32 S2 p. 53-
1 p.
 article
48 PP-1-13 Breast cancer cell mediated control of human stromelysin 3 (ST3) promoter activity Ahmad, A.
 1996
 32 S2 p. 12-
1 p.
 article
49 PP-4-32 Breast cancer in albania: incidence and preliminary results of screening Amanti, C.
 1996
 32 S2 p. 32-
1 p.
 article
50 PP-8-10 Breast cancer in 1980–1995: Meta-analysis of dose intensity (neoadjuvant chemotherapy) Shparik, J.
 1996
 32 S2 p. 50-
1 p.
 article
51 PP-2-18 breast cancer in women over 70 Veys, I.
 1996
 32 S2 p. 17-
1 p.
 article
52 PP-9-12 Breast cancer oestrogen-receptor negative tumors, PS2 expression and DFI Filipović, S.
 1996
 32 S2 p. 57-
1 p.
 article
53 PP-6-22 Breast Cancer Outcome after Pregnancy Hallé, O.
 1996
 32 S2 p. 42-
1 p.
 article
54 PP-10-4 Breast care nursing intervention survey Cotton, P.
 1996
 32 S2 p. 59-
1 p.
 article
55 PP-2-13 Breast conserving surgery. is it too expensive? Norum, J.
 1996
 32 S2 p. 17-
1 p.
 article
56 PP-2-21 Breast reconstruction following mastectomy: Our experience Galassi, G.
 1996
 32 S2 p. 18-
1 p.
 article
57 PP-4-25 Breast screening: A 7-Year experience in the Northeast of France Netter, E.
 1996
 32 S2 p. 31-
1 p.
 article
58 PP-4-35 Breast screening for women aged < 50 — results from a family history clinic Kollias, J.
 1996
 32 S2 p. 33-
1 p.
 article
59 PP-2-22 Breast surgery without any antibiotical prophylaxis Amanti, C.
 1996
 32 S2 p. 18-
1 p.
 article
60 PP-4-23 CA 15-3, CEA and TPS for Monitoring metastatic breast cancer patients — a multicenter study van Dalen, A.
 1996
 32 S2 p. 31-
1 p.
 article
61 PP-3-18 can pretreatment mammograms predict local recurrence after breast-conserving therapy? Voogd, A.C.
 1996
 32 S2 p. 23-
1 p.
 article
62 PP-7-16 Cardioxane still induces effective cardioprotection in anthracycline pretreated breast cancer patients Maral, J.
 1996
 32 S2 p. 48-
1 p.
 article
63 PP-5-6 Castration and Tamoxifen Versus Chemotherapy (FAC) for Premenopausal, Node and Receptors Positive Breast Cancer Patients: A Randomized Trial with a 7 Years Median Follow Up Roché, H.
 1996
 32 S2 p. 35-
1 p.
 article
64 PP-2-23 Changing attitudes among surgeons towards breast-conserving treatment of early breast cancer Voogd, A.C.
 1996
 32 S2 p. 18-19
2 p.
 article
65 PP-8-13 Chemoradiotherapy in complex treatment of locally advanced breast cancer Letyagin, V.
 1996
 32 S2 p. 51-
1 p.
 article
66 PP-8-33 Chemotherapy for metastatic breast cancer: Ten years experience Piazza, E.
 1996
 32 S2 p. 54-
1 p.
 article
67 PP-1-12 Chemotherapy-induced diversification of DNA profiles in breast cancer Zaloudik, J.
 1996
 32 S2 p. 12-
1 p.
 article
68 PP-2-6 chest wall resection in 44 patients with recurrent breast cancer: indications and results Rutgers, E.J.Th.
 1996
 32 S2 p. 15-
1 p.
 article
69 PP-1-17 Circulating tumor markers (CEA, MCA, CA 15.3, CA 549) in the diagnosis breast cancer recurrence after surgery: 5-Year results Zamagni, C.
 1996
 32 S2 p. 13-
1 p.
 article
70 PP-9-14 Clinical significance of pyrimidine nucleoside phosphorytese staining in breast cancer Tanaka, S.
 1996
 32 S2 p. 57-
1 p.
 article
71 PP-5-5 CMF vs Tamoxifen (TAM) Plus Goserelin (GOS) as Adjuvant Treatment of ER Positive (+VE) Pre-Perimenopausal Breast Cancer Patients (PTS). Preliminary Results of an Ongoing Italian Breast Cancer Adjuvant Study Group (GROCTA) Trial Boccardo, F.
 1996
 32 S2 p. 35-
1 p.
 article
72 PP-8-19 Combination of intraarterial chemotherapy with endocrine therapy in the treatment of liver metastases of breast cancer Yayoi, E.
 1996
 32 S2 p. 52-
1 p.
 article
73 PP-8-1 Combined estroyen suppression and receptor (ER) blockade by buserelin (LHRH-A) and tamoxifen (TAM) in premenopausal metastatic breast cancer: Preliminary results of a 3-arm randomized study (EORTC 10881) Klijn, J.G.M.
 1996
 32 S2 p. 49-
1 p.
 article
74 PP-10-1 Communicating the results of breast biopsies over the telephone and in person. Is there a difference? Campbell, L.
 1996
 32 S2 p. 58-
1 p.
 article
75 PP-2-16 Compressive bandage and postoperative complications to breast surgery. a randomised trial Hørby, J.
 1996
 32 S2 p. 17-
1 p.
 article
76 PP-2-9 conservative approach in subareolar breast cancers: A series of 37 patients Bussières, E.
 1996
 32 S2 p. 16-
1 p.
 article
77 PP-3-16 conservative treatment for intraductal carcinoma of the breast with surgery and radiotherapy Amichetti, M.
 1996
 32 S2 p. 23-
1 p.
 article
78 PP-1-21 Correlational study of microangiographic and immunohistochemical techniques for tumour vascularisation Dalal, A.V.
 1996
 32 S2 p. 13-
1 p.
 article
79 PP-1-8 Cyclin D1 expression and response to tamoxifen treatment for metastatic breast cancer Barnes, D.M.
 1996
 32 S2 p. 11-
1 p.
 article
80 PP-1-10 Cytogenetic analysis in short term culture of breast cancer in Korea women Bae, J.W.
 1996
 32 S2 p. 11-12
2 p.
 article
81 PP-1-4 Detection of isolated tumor cells in peripheral blood and bone marrow in stage I and II breast cancer Kaaresen, R.
 1996
 32 S2 p. 10-
1 p.
 article
82 PP-8-16 Detection of Liver Metastases in Advanced Breast Cancer Vinholes, A.P.B.
 1996
 32 S2 p. 51-
1 p.
 article
83 PP-1-19 Determination of cytosol ERBB-2 protein in primary breast cancer Imoto, S.
 1996
 32 S2 p. 13-
1 p.
 article
84 PP-6-10 Diabetes mellitus — a prognostic factor in breast cancer? Schmidt, G.
 1996
 32 S2 p. 40-
1 p.
 article
85 PP-2-4 diagnosis of intramammary recurrences of breast cancer after conservative treatment Distante, V.
 1996
 32 S2 p. 15-
1 p.
 article
86 PP-5-10 Direct comparisons of adjuvant chemo-endocrine therapy in operable breast cancer stratified by ER and menopausal status Nomura, Y.
 1996
 32 S2 p. 36-
1 p.
 article
87 PP-6-23 DNA Image and Flow Cytometry Analyses in Breast Cancer Fine-Needle Cytopunctures Spyratos, F.
 1996
 32 S2 p. 42-
1 p.
 article
88 PP-9-9 DNA image cytometry (ICM), oncogenes and prognostic factors in breast cancer Schlotter, C.M.
 1996
 32 S2 p. 56-
1 p.
 article
89 PP-5-4 Does Tamoxifen (Tam) increase bone resorption in premenopausal women? Bundred, N.J.
 1996
 32 S2 p. 35-
1 p.
 article
90 PP-7-6 Dose dense epirubicin (E) and paclitaxel (P) with G-CSF in metastatic breast cancer (MBC) Nortier, J.
 1996
 32 S2 p. 46-
1 p.
 article
91 PP-7-12 Dose-finding study of weekly oral vinorelbine (VRL) in patients (PTS) with advanced breast cancer (ABC): preliminary results Chevallier, B.
 1996
 32 S2 p. 47-
1 p.
 article
92 PP-8-3 Double-blind trial in postmenopausal (PMP) women with advanced breast cancer (ABC) showing a dose-effect and superiority of 2.5 mg letrozole over megestrol acetate (MA) Smith, I.
 1996
 32 S2 p. 49-
1 p.
 article
93 PP-3-1 Ductal carcinoma in situ (dcis) of the breast: About 706 cases examined from 1971 to 1995 de Lara, C.Tunon
 1996
 32 S2 p. 20-
1 p.
 article
94 PP-3-2 Ductal carcinoma in situ: Radiosurgical conservative treatment in 122 cases. Analysis of local recurrence factors Cutuli, B.
 1996
 32 S2 p. 20-
1 p.
 article
95 PP-4-7 Early diagnosis of inherited breast cancer Møller, P.
 1996
 32 S2 p. 28-
1 p.
 article
96 PP-8-32 EGR-R in locally advanced and inflammatory breast carcinomas Ne<sković-Konstantinović, Z.
 1996
 32 S2 p. 54-
1 p.
 article
97 PP-8-20 Epirubicin (E) + navelbine (NVB) as first line chemotherapy in advanced breast cancer (ABC) patients (PTS): A multicentric phase II study Baldini, E.
 1996
 32 S2 p. 52-
1 p.
 article
98 PP-7-3 Epirubicin (E) plus paclitaxel (P) in advanced breast cancer: A regimen with high activity and low cardiac toxicity which mobilizes peripheral blood stem cells Conte, P.F.
 1996
 32 S2 p. 45-
1 p.
 article
99 PP-6-18 Estrogen-Induced Proteins in Breast Carcinoma Nikolić-Vukosavljević, D.
 1996
 32 S2 p. 41-
1 p.
 article
100 PP-10-2 Evaluation of quality of life after conservative treatment for intraductal carcinoma of the breast Caffo, O.
 1996
 32 S2 p. 58-
1 p.
 article
101 PP-4-21 Evaluation of the european pilot project in navarra; A high breast cancer detection rate in the first round and a low rate in the second round van Marle, M.E.
 1996
 32 S2 p. 30-
1 p.
 article
102 PP-1-6 Expression of BCL-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to peri-operative chemotherapy van Slooten, H.-J.
 1996
 32 S2 p. 11-
1 p.
 article
103 PP-1-23 Expression of thymidine phosphorylase in mammary carcinomas and its relationship to angiogenesis Yoshida, H.
 1996
 32 S2 p. 14-
1 p.
 article
104 PP-9-5 Expression of uPA, c-erbB2, EGF-R and p53 in 488 primary breast cancer Spyratos, F.
 1996
 32 S2 p. 56-
1 p.
 article
105 PP-9-8 Fatty acid synthetase (FAS) and survival in breast cancer Hähnel, R.
 1996
 32 S2 p. 56-
1 p.
 article
106 PP-5-14 FEC-75 Plus G-CSF in locally advanced breast carcinoma Artal, A.
 1996
 32 S2 p. 37-
1 p.
 article
107 PP-8-2 First line tamoxifen for invasive hormonal sensitive non metastatic breast carcinomas in young postmenopausal patients Mauriac, L
 1996
 32 S2 p. 49-
1 p.
 article
108 PP-8-14 five-year results of a multimodal management of stage III B breast cancer Massidda, B.
 1996
 32 S2 p. 51-
1 p.
 article
109 PP-9-18 French association of cytometry quality control report on FCM-DNA content and S-phase fraction D'Hautcourt, J.-L.
 1996
 32 S2 p. 58-
1 p.
 article
110 PP-4-6 Germline mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer Sobol, H.
 1996
 32 S2 p. 28-
1 p.
 article
111 PP-8-11 Half body (HBI) and total body (TBI) irradiation in disseminated breast cancer patients (PTS) Vinogradov, V.
 1996
 32 S2 p. 50-51
2 p.
 article
112 PP-7-8 Hexadecyl phosphocholine in the topical treatment of skin metastasized breast cancer Gaafar, R.M.
 1996
 32 S2 p. 46-
1 p.
 article
113 PP-5-3 High dose chem otherapy (HDCT) with autologous blood cell (BC) Support in Metastatic Breast Cancer (MBC) Glück, S.
 1996
 32 S2 p. 35-
1 p.
 article
114 PP-5-17 High-dose cyclophosphamide (CTX), Mitoxantrone (MXT), and Paclitaxel (Taxol®, TXL) for the treatment of metastatic breast cancer (MBC) with blood cell support Glück, S.
 1996
 32 S2 p. 37-
1 p.
 article
115 PP-5-11 High dose mitoxantrone and cyclophosphamide with GM-CSF in first line chemotherapy of breast cancer Astone, A.
 1996
 32 S2 p. 36-
1 p.
 article
116 PP-9-13 High positive rate of ps2 expression in forefront intraductal cancerous area in breast cancer Yamakawa, T.
 1996
 32 S2 p. 57-
1 p.
 article
117 PP-4-40 Histologic findings in prophylactic mastectomy specimens from women with hereditary risk factors Verhoog, L.C.
 1996
 32 S2 p. 34-
1 p.
 article
118 PP-6-12 Histopathological characteristics of ductal carcinoma in situ (DCIS) of the breast. A comparison before and after the introduction of mammographic screening Idvall, I.
 1996
 32 S2 p. 40-
1 p.
 article
119 PP-3-22 hypofractionated radiotherapy of breast cancer in elderly Golubičić, I.
 1996
 32 S2 p. 24-
1 p.
 article
120 PP-4-19 Imaging of tumours in breast cancer patients with the estrogen receptor specific radioligand Z-[I-123]MIVE Rijks, L.J.M.
 1996
 32 S2 p. 30-
1 p.
 article
121 PP-2-5 immediate breast reconstruction after mastectomy for cancer Ringberg, A.
 1996
 32 S2 p. 15-
1 p.
 article
122 PP-2-14 Immediate breast reconstruction (IBR) in breast cancer patients Blokhin, S.N.
 1996
 32 S2 p. 17-
1 p.
 article
123 PP-9-1 Immunohistochemical analyses of proliferative activity in breast carcinomas with medullary features Jensen, V.
 1996
 32 S2 p. 55-
1 p.
 article
124 PP-9-7 Immunohistochemical expression of c-erbB-2, p53, and bcl-2 oncoprotein and response to endocrine therapy in advanced breast cancer Osaki, A.
 1996
 32 S2 p. 56-
1 p.
 article
125 PP-5-9 Impact of adjuvant chemotherapy in conservative treatment of breast cancer T1-2NOMO Semiglazov, V.F.
 1996
 32 S2 p. 36-
1 p.
 article
126 PP-6-2 Incidence and prognostic value of routine clinical parameters in 2273 patients with primary breast cancer treated between 1978–1990 Klijn, J.G.M.
 1996
 32 S2 p. 38-
1 p.
 article
127 PP-4-1 Influence of mammographic patterns on breast cancer screening performance van Gils, C.H.
 1996
 32 S2 p. 27-
1 p.
 article
128 PP-8-29 Initial characteristics and outcome of infiltrating lobular carcinomas (ILC): A retrospective study about 737 patients Quénel, N.
 1996
 32 S2 p. 54-
1 p.
 article
129 PP-1-14 Integrins αvβ1 and αvβ5 function as breast cancer cell vitronectin receptors Meyer, T.
 1996
 32 S2 p. 12-
1 p.
 article
130 PP-5-19 Intensification chemotherapy (IQ) with autologous peripheral blood progenitor cell (PBPC) support in patients with breast cancer: Results of the transplantation procedure Constenia, M.
 1996
 32 S2 p. 38-
1 p.
 article
131 PP-5-12 Intensive chemotherapy program with autologous bone marrow transplantation (ABMT) in non metastatic inflammatory breast cancer: Mature results Roche, H.
 1996
 32 S2 p. 36-
1 p.
 article
132 PP-5-7 Interest of irradiation and AVCF chemotherapy in 241 Node-positive stage ii breast cancers: Late results Charrier, S.
 1996
 32 S2 p. 35-
1 p.
 article
133 PP-8-31 Intra-arterial liver chemoinfusion in patients with metastatic breast cancer Jamitzky, T.
 1996
 32 S2 p. 54-
1 p.
 article
134 PP-2-17 Intra operative HDR boost in BCT Hoekstra, C.J.M.
 1996
 32 S2 p. 17-
1 p.
 article
135 PP-3-11 Intra operative iridium versus external beam boost in breast conservation; Boost volumes and local control van Tienhoven, G.
 1996
 32 S2 p. 22-
1 p.
 article
136 PP-10-5 Involving a trained psychologists at the time of breast cancer (BC) surgery: Effects on communication and psychosocial adjustment Aimont, M.
 1996
 32 S2 p. 59-
1 p.
 article
137 PP-3-15 is axillary dissection necessary in breast cancer conservative treatment? An historical series Nogaret, J.-M.
 1996
 32 S2 p. 23-
1 p.
 article
138 PP-3-3 Is axillary node dissection (A.N.D.) useful for microinfiltrative breast carcinoma (MIBC)? Floquet, A.
 1996
 32 S2 p. 20-
1 p.
 article
139 PP-1-15 Is Cowden disease gene a tumor suppressor gene or not? Coulon, V.
 1996
 32 S2 p. 12-
1 p.
 article
140 PP-3-20 local excision with a 10 mm margin as sole treatment for ductal carcinoma in situ (dcis) of the breast Sibbering, D.M.
 1996
 32 S2 p. 24-
1 p.
 article
141 PP-2-1 Localisation of impalpable breast lesions — a surgical approach Rovere, G.Querci della
 1996
 32 S2 p. 14-
1 p.
 article
142 PP-3-14 Local recurrences (lr) after radiosurgical breast conservative treatment (BCT): Frequnce, risk factors and outcome Cutuli, B.
 1996
 32 S2 p. 22-23
2 p.
 article
143 PP-3-21 loco-regional recurrences after mastectomy in breast cancer Jager, J.
 1996
 32 S2 p. 24-
1 p.
 article
144 PP-8-18 Long-term palliation of metastatic bone pain with intermittent pamidronate Zekri, I.
 1996
 32 S2 p. 52-
1 p.
 article
145 PP-3-7 Long term time course of breast recurrence after breast-conservative treatment of small breast cancer Giraud, P.
 1996
 32 S2 p. 21-
1 p.
 article
146 PP-9-16 Low and high molecular weight cytokeratins express the differentiation of invasive breast carcinoma Takei, H.
 1996
 32 S2 p. 58-
1 p.
 article
147 PP-1-3 Luminometric immunoassays of P53 and uPA in 600 node-negative breast cancers; first evaluation of the prognostic values Peyrat, J.-Ph.
 1996
 32 S2 p. 10-
1 p.
 article
148 PP-3-13 lymphoedema after primary treatment for breast cancer in elderly women Tengrup, I.
 1996
 32 S2 p. 22-
1 p.
 article
149 PP-8-34 Metastatic breast cancer management in France Launois, R.
 1996
 32 S2 p. 55-
1 p.
 article
150 PP-8-22 Metastatic dissemination in the inflammatory breast cancer (IBC) Burić, M.
 1996
 32 S2 p. 52-53
2 p.
 article
151 PP-1-2 Modulation of human stromelysin-3 (ST3) promoter activity by human breast cancer cell conditioned medium Ahmad, A.
 1996
 32 S2 p. 10-
1 p.
 article
152 PP-8-30 MRF (Mitomycin, folinic acid and 5FU) for metastatic breast cancer — A prospective pilot study Lange, O.F.
 1996
 32 S2 p. 54-
1 p.
 article
153 PP-4-16 Mutational study of BRCA1 gene in familial breast cancer Garcia, E.
 1996
 32 S2 p. 29-
1 p.
 article
154 PP-7-2 Neoadjuvant chemotherapy by VEC regimen in breast cancer. preliminary results of a phase II trial Dohollou, N.
 1996
 32 S2 p. 45-
1 p.
 article
155 PP-5-2 Neo-Adjuvant High-Dose FEC Regimen (H-FEC) with G-CSF (G) for Large Early Breast Cancer Llombart Cussac, A.
 1996
 32 S2 p. 34-
1 p.
 article
156 PP-1-22 Non-invasive measurement of antioestrogen activity in the breast Harding, C.
 1996
 32 S2 p. 13-14
2 p.
 article
157 PP-4-20 Nonpalpable opacities on mammograms: Histopathological-mammographic correlations of 304 cases Cherel, P.
 1996
 32 S2 p. 30-
1 p.
 article
158 PP-9-11 Oncogene evaluation (c-int2, c-erb 82, c-myc) in 265 breast carcinoma pT1-T2, pN0-N1, M0 Bolla, M.
 1996
 32 S2 p. 57-
1 p.
 article
159 PP-8-23 Oral clodronate for bone metastases in breast cancer Projević, M.
 1996
 32 S2 p. 53-
1 p.
 article
160 PP-7-15 Org-OD14 significantly inhibits DMBA induced mammary tumor growth in rats: Effects of combination therapy with tamoxifen or the antiprogestin org-31710 Setyono-Han, B.
 1996
 32 S2 p. 47-48
2 p.
 article
161 PP-4-22 Overweight and hormone receptor positive breast carcinoma in postmenopausal women Weber, B.
 1996
 32 S2 p. 30-31
2 p.
 article
162 PP-7-17 Paclitaxel and carboplatin with G-CSF support in advanced breast cancer resistant to anthracyclines Aravantinos, G.
 1996
 32 S2 p. 48-
1 p.
 article
163 PP-7-18 Paclitaxel combinations with weekly high dose 5-FU/Folinic acid and cisplatin in the treatment of metastatic breast cancer — there is a possible role of combining paclitaxel with anthracycline non cross resistant chemotherapeutic agents in the first and second line treatment I Klaassen, U.
 1996
 32 S2 p. 48-
1 p.
 article
164 PP-8-6 Paclitaxel (P) versus doxorublcin (D) as first line chemotherapy (CT) in advanced breast cancer (ABC): A randomized trial with crossover of the EORTC-IDBBC in collaboration with EORTC-ECSG Bruning, P.
 1996
 32 S2 p. 50-
1 p.
 article
165 PP-2-15 Pain and other symptoms during the first year after surgery for breast cancer Tasmuth, T.
 1996
 32 S2 p. 17-
1 p.
 article
166 PP-3-10 Patients experience with immediate breast reconstruction Rosenquist, S.
 1996
 32 S2 p. 22-
1 p.
 article
167 PP-2-7 pattern of lymphatic dissemination in breast cancer Kapteijn, B.A.E.
 1996
 32 S2 p. 15-16
2 p.
 article
168 PP-3-6 Patterns of Diagnosis of 350 Breast Failures in Patients Treated with Conservative Breast surgery, axillary dissection and RT for Breast Cancer De Lafonten, B.
 1996
 32 S2 p. 21-
1 p.
 article
169 PP-9-17 PCNA Labeling index and expression of pS2 and c-erbB-2 protein in primary breast cancer Horiguchi, Jun
 1996
 32 S2 p. 58-
1 p.
 article
170 PP-7-13 Phase I–II trial of mitoxantrone (M) and taxot (T) in advanced breast cancer (ABC) Costanzo, F.Di
 1996
 32 S2 p. 47-
1 p.
 article
171 PP-8-15 Phase II studies with Rlvfzor® (Vorozole) in Advanced Breast Cancer Piccart, M.
 1996
 32 S2 p. 51-
1 p.
 article
172 PP-7-1 phase II study of liarozole in advanced breast cancer patients 1996
 32 S2 p. 45-
1 p.
 article
173 PP-7-5 phase II study of paclitaxel (P) and eplrubicin (E) as first-line therapy in patients (PTS) with metastatic breast cancer (MBC) Thomssen, Ch.
 1996
 32 S2 p. 46-
1 p.
 article
174 PP-7-11 Phase I study of combination docetaxel with cyclophosphamide in the treatment of metastatic breast cancer Enomoto, K
 1996
 32 S2 p. 47-
1 p.
 article
175 PP-7-4 Phase l ll study of taxol® (paclitaxel) in combination with epirubicin and cyclophosphamide without G-CSF as a first line treatment of metastatic breast carcinoma (MBC) Hulin, M.Tubiana
 1996
 32 S2 p. 45-
1 p.
 article
176 PP-1-18 Plasma c-erbB2 concentrations and response to chemotherapy in breast cancer Révillion, F.
 1996
 32 S2 p. 13-
1 p.
 article
177 PP-1-26 Polymorphism of estrogen receptors from primary breast cancers Maaroufi, Y.
 1996
 32 S2 p. 14-
1 p.
 article
178 PP-5-15 Postoperative adjuvant randomized trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with Stage II breast cancer Morimoto, T.
 1996
 32 S2 p. 37-
1 p.
 article
179 PP-6-16 prediction of relapse in patients with breast cancer by blood flow analysis using color doppler ultrasound Konishi, Y.
 1996
 32 S2 p. 41-
1 p.
 article
180 PP-1-24 Prediction of the effect of 5′-deoxy-5-fluorouridine (5′-DFUR) by the status of angiogenic enzyme thymidine phosphorylase expression in advanced breast cancer patients Tominaga, T.
 1996
 32 S2 p. 14-
1 p.
 article
181 PP-6-8 Prediction of tumor response to neoadjuvant chemotherapy in operable breast cancer Briffod, M.
 1996
 32 S2 p. 39-
1 p.
 article
182 PP-6-14 32P Relative Uptaking by a Tumor (32PRUT) is a Factor of Prognosis in Breast Cancer (BC) Patients Portnoj, S.M.
 1996
 32 S2 p. 40-41
2 p.
 article
183 PP-5-1 Preliminary analysis of a randomized phase II study of high-dose chemotherapy in high-risk breast cancer Rutgers, E.J.Th.
 1996
 32 S2 p. 34-
1 p.
 article
184 PP-6-19 Pre-Operative Diagnosis and Establishment of Breast Cancer Phenotypic Features of Prognostic Relevance on Routine Fine-Needle Cytological Samples Lesec, G.
 1996
 32 S2 p. 41-
1 p.
 article
185 PP-6-21 Preoperative Values of CA 15.3 and Disease-Free Interval (DPI) in Breast Cancer Mijailović, M.
 1996
 32 S2 p. 42-
1 p.
 article
186 PP-3-8 Prognosis after salvage treatment for local-regional recurrence of mastectomy or breast conservation in eortic trial 10801 van Tienhoven, G.
 1996
 32 S2 p. 21-
1 p.
 article
187 PP-4-5 Prognosis in patients with carcinoma in situ of the breast. A population based study in Sweden Wärnberg, F.
 1996
 32 S2 p. 27-28
2 p.
 article
188 PP-6-9 Prognostic significance of epidermal growth factor receptor and estrogen receptor in advanced breast cancer Gaafar, R.M.
 1996
 32 S2 p. 39-40
2 p.
 article
189 PP-6-4 Prognostic Significance of Obvious Peritumoral Emboli in 2692 Primary Operable Breast Carcinoma de Mascarel, I.
 1996
 32 S2 p. 39-
1 p.
 article
190 PP-6-11 Prognostic significance of p53 protein accumulation in Male Breast Cancer (MBC) Massidda, B.
 1996
 32 S2 p. 40-
1 p.
 article
191 PP-9-3 Prognostic value of P21/WAF1 and P53 expression in breast carcinoma: An immunohistochemical study on 261 cases with long term follow up Caffo, O.
 1996
 32 S2 p. 55-
1 p.
 article
192 PP-6-17 psychological factors as prognosticators in metastatic breast cancer Jensen, A.B.
 1996
 32 S2 p. 41-
1 p.
 article
193 PP-10-3 Psychologic impact of breast cancer diagnosis: Coping strategies Cousson, F.
 1996
 32 S2 p. 58-59
2 p.
 article
194 PP-1-20 Psychosocial correlates of oestrogen and progesterone receptors in breast cancer: Results of three consecutive studies Razavi, D.
 1996
 32 S2 p. 13-
1 p.
 article
195 PP-1-5 Quantitative determination of c.erbB.2 oncoprotein in 1065 human breast tumours by an enzymoimmunoassay. Comparison with the clinico-biological parameters: A multicentric study Koscielny, S.
 1996
 32 S2 p. 10-11
2 p.
 article
196 PP-4-2 Radiation risk of mammography related to benefit in screening programs: A favourable balance? Beemsterboer, P.M.M.
 1996
 32 S2 p. 27-
1 p.
 article
197 PP-2-10 radical mastectomy by means of a periareolar incision followed by immediate reconstruction Figueira Fo, Antonio S.S.
 1996
 32 S2 p. 16-
1 p.
 article
198 PP-5-13 Radical radiotherapy and effects of tamoxifen in patients with histologically positive stumps after breast preservation operations Kusama, M.
 1996
 32 S2 p. 36-37
2 p.
 article
199 PP-4-28 Randomised controlled trial comparing the effectiveness of rapid diagnosis and routine outpatient clinics Dey, P.
 1996
 32 S2 p. 31-32
2 p.
 article
200 PP-4-3 Reduction of breast cancer mortality due to mammographic screening of elderly women Van Dijck, J.A.A.M.
 1996
 32 S2 p. 27-
1 p.
 article
201 PP-8-9 Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving chemotherapy (CT), by monthly pamidronate sodium (PAM) (AREDIA®) infusion Hortobagyi, G.N.
 1996
 32 S2 p. 50-
1 p.
 article
202 PP-8-8 Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly pamidronate sodium (AREDIA®) infusion Theriault, R.
 1996
 32 S2 p. 50-
1 p.
 article
203 PP-1-1 Refinement of the two regions on the long arm of chromosome 16 involved in breast cancer Bonnet-Dorion, F.
 1996
 32 S2 p. 10-
1 p.
 article
204 PP-8-21 Response to neoadjuvant chemotheraphy in locally advanced breast cancer Purkalne, G.
 1996
 32 S2 p. 52-
1 p.
 article
205 PP-4-12 Results of mass screening for breast cancer in atomic bomb survivors resident in Hiroshima Kuroi, K.
 1996
 32 S2 p. 29-
1 p.
 article
206 PP-4-13 Review of 260 non palpable breast lesions Janssen, A.
 1996
 32 S2 p. 29-
1 p.
 article
207 PP-2-3 risk factors and their importance in complications alter breast surgery Hørby, J.
 1996
 32 S2 p. 15-
1 p.
 article
208 PP-3-5 Risk factors for local recurrence after breast-conserving treatment: Results of a multicentre case-control study 1996
 32 S2 p. 21-
1 p.
 article
209 PP-3-23 risk factors of local recurrence after breast conserving therapy Elkhuizen, P.H.M.
 1996
 32 S2 p. 24-
1 p.
 article
210 PP-4-38 Screening for BRCA1 and BRCA2 Germline Mutations — Analysis of 50 Families with Clustering of Cancer Hogervorst, F.B.L.
 1996
 32 S2 p. 33-
1 p.
 article
211 PP-4-26 Second cancers after breast conservative treatment (BCT) Cutuli, B.
 1996
 32 S2 p. 31-
1 p.
 article
212 PP-4-8 Secular trends in mortality in four large kindreds with hereditary breast-ovarian cancer Hille, E.T.M.
 1996
 32 S2 p. 28-
1 p.
 article
213 PP-2-28 Seroma as complication to surgery in breast cancer. Randomized study comparing drainage and compressive dressing of the wound Guldvog, I.
 1996
 32 S2 p. 19-20
2 p.
 article
214 PP-6-13 Significance of some morphological signs for treatment results in breast cancer T1-2NOMO patients Ermilova, V.D.
 1996
 32 S2 p. 40-
1 p.
 article
215 PP-4-37 Standards, options and recommendations (sor) project from the FNCLCC: Non metastatic breast cancer Blanc-Vincent, M.P.
 1996
 32 S2 p. 33-
1 p.
 article
216 PP-4-14 Stereotaxic fine-needle aspiration cytology in the detection of non palpable breast cysts: An alternative to ultrasound guidance Barreau, B.
 1996
 32 S2 p. 29-
1 p.
 article
217 PP-4-24 Stereotaxic large-core needle biopsy of breast microcalcifications Troufléau, Ph.
 1996
 32 S2 p. 31-
1 p.
 article
218 PP-1-25 Subclinical thyroid dysfunction in patients with breast cancer Millán, J.
 1996
 32 S2 p. 14-
1 p.
 article
219 PP-4-33 Surveillance for contralateral breast cancer: The mode of diagnosis and subsequent stage Kaas, R.
 1996
 32 S2 p. 32-
1 p.
 article
220 PP-6-20 Survival Following First Episode of Hypercalcaemia in Breast Cancer Patients Kristensen, B.
 1996
 32 S2 p. 41-42
2 p.
 article
221 PP-7-7 Taxol. (paclitaxel), epirubicin and cyclophosphamide (TEC) in the treatment of metastatic breast cancer (MBC): preliminary results of a phase I study Nabholtz, J.-M.
 1996
 32 S2 p. 46-
1 p.
 article
222 PP-4-41 The age distribution and biological characteristics of interval cancers in the North West region of the NHSBSP Threlfair, A.G.
 1996
 32 S2 p. 34-
1 p.
 article
223 PP-8-25 The clinical relevance of static disease for 6 months on endocrine therapy in patients with breast cancer Robertson, J.F.R.
 1996
 32 S2 p. 53-
1 p.
 article
224 PP-8-24 The effect of vorozole on tissue aromatase activity in advanced breast cancer de Jong, P.Chr.
 1996
 32 S2 p. 53-
1 p.
 article
225 PP-4-31 The improvement of aspiration biopsy cytology by ultrasound guided high power aspiration Wakita, K.
 1996
 32 S2 p. 32-
1 p.
 article
226 PP-6-15 The Levels of Estrogen Receptors (ER) and Progesterone Receptors (PR) and Treatment Results in Breast Cancer (BC) T1-2NOMO Patients Kushlinsky, N.E.
 1996
 32 S2 p. 41-
1 p.
 article
227 PP-2-27 The organ-keeping operations in the treatment of the breast cancer T1-2 NO MO Gantsev, S.H.
 1996
 32 S2 p. 19-
1 p.
 article
228 PP-4-36 The position of the internal mammary lymphnode chain by scintigraphy and sonography: A comparative study Scheijmans, L
 1996
 32 S2 p. 33-
1 p.
 article
229 PP-9-4 The predictive value of the urokinase system of plasminogen activation in recurrent breast cancer Foekens, J.A.
 1996
 32 S2 p. 55-56
2 p.
 article
230 PP-6-6 The Prognostic Importance of Tumour Grade in Lymph Node Positive Breast Cancer Kollias, J.
 1996
 32 S2 p. 39-
1 p.
 article
231 PP-9-10 The prognostic significance of protein tyrosin kinase, ER, PR, and the mitotic activity index in 86 primary breast cancer patients Bayrak, J.
 1996
 32 S2 p. 57-
1 p.
 article
232 PP-4-11 The relationship between early life experience and risk for breast cancer in premenopausal women Liu, L.J.
 1996
 32 S2 p. 28-29
2 p.
 article
233 PP-4-29 The role of digital processing mammography in diagnosis of breast cancer Tsouskas, L.I.
 1996
 32 S2 p. 32-
1 p.
 article
234 PP-6-3 The selection of patients with DCIS for a clinical randomised trial: Differences between large participating centres Bijker, N.
 1996
 32 S2 p. 38-39
2 p.
 article
235 PP-2-20 The timing of drainage removal in breast surgery Amanti, C.
 1996
 32 S2 p. 18-
1 p.
 article
236 PP-9-6 The use of molecular markers to predict response to preoperative chemotherapy: Fact or fiction? van Slooten, H.-J.
 1996
 32 S2 p. 56-
1 p.
 article
237 PP-9-2 The value of nm23 protein expression and tumor angiogenesis as a prognostic indicator in breast cancer of korean women Lee, E.S.
 1996
 32 S2 p. 55-
1 p.
 article
238 PP-4-4 The yield of an intensive follow-up program for women at increased risk for breast cancer Rutgers, E.J.Th.
 1996
 32 S2 p. 27-
1 p.
 article
239 PP-7-14 Third-line chemotherapy with bendamustin for metastatic breast cancer — A prospective pilot study Jamitzky, T.
 1996
 32 S2 p. 47-
1 p.
 article
240 PP-6-1 Time since birth is a prognostic factor in primary breast cancer Kroman, Niels
 1996
 32 S2 p. 38-
1 p.
 article
241 PP-1-11 Transferrin receptor (cd71) expression by human breast cancer cells Artamonova, E.V.
 1996
 32 S2 p. 12-
1 p.
 article
242 PP-1-9 Tumor-associated lymphomonocytes from neoplastic effusions of patients with different primary tumors including breast cancers are able to release cytokines Mantovani, G.
 1996
 32 S2 p. 11-
1 p.
 article
243 PP-4-18 Ultrasound-guided localisation of impalpable breast lesions Campbell, L
 1996
 32 S2 p. 30-
1 p.
 article
244 PP-8-12 Unclear value of salvage chemotherapy after failure to first-tine 5-fluorouracil, epirubicin, cyclophosphamide (FEC) regimen for metaatatic breafit cancer Gardin, G.
 1996
 32 S2 p. 51-
1 p.
 article
245 PP-8-28 Usefulness of a combination chemoendocrine therapy of mitoxantrone, doxifluridine and medroxyprogesterone acetate for anthracycline-resistant advanced or metastatic breast cancer Iino, Y.
 1996
 32 S2 p. 53-54
2 p.
 article
246 PP-4-17 Use of positron emission and computed tomography in evaluation of brachial plexopathy in breast cancer patients Ahmad, A.
 1996
 32 S2 p. 29-30
2 p.
 article
247 PP-4-27 Use of prevention modalities for breast cancer: survey on 2889 self-administrated questionnaires Caffo, O.
 1996
 32 S2 p. 31-
1 p.
 article
248 PP-2-24 Variants of immediate breast reconstruction in breast cancer treatment Demidov, V.P.
 1996
 32 S2 p. 19-
1 p.
 article
249 PP-7-9 Weekly vinorelbine (VRB) as single agent for advanced breast cancer (ABC) Santoro, A.
 1996
 32 S2 p. 46-
1 p.
 article
250 PP-3-4 10 years experience in external beam radiotherapy and interstitial hdr192 iridium implantation in the treatment of breast cancer Hammer, J.
 1996
 32 S2 p. 20-21
2 p.
 article
251 PP-3-17 young age and breast conservative treatment Moreno, F.
 1996
 32 S2 p. 23-
1 p.
 article
252 Subject index 1996
 32 S2 p. 67-68
2 p.
 article
253 SY-9-4 Aspects of Breast Reconstruction Lehman, M.
 1996
 32 S2 p. 44-
1 p.
 article
254 SY-4-3 Cell surface mucins in the biology and treatment of breast cancer Miles, D.W.
 1996
 32 S2 p. 25-
1 p.
 article
255 SY-9-2 Communication between Breast Cancer Patients and Physicians Fallowfield, L.J.
 1996
 32 S2 p. 44-
1 p.
 article
256 SY-7-1 Comparison of Technics for ER estimation Thorpe, S.
 1996
 32 S2 p. 43-
1 p.
 article
257 SY-2-4 DCIS: Quality control of conservative treatment Rutgers, E.J.Th.
 1996
 32 S2 p. 8-
1 p.
 article
258 SY-1-2 Genes predisposing to breast cancer Devilee, P.
 1996
 32 S2 p. 7-
1 p.
 article
259 SY-7-3 Growth factor receptors Klijn, J.G.M.
 1996
 32 S2 p. 43-
1 p.
 article
260 SY-6-4 hormone replacement therapy Pritchard, K.
 1996
 32 S2 p. 26-
1 p.
 article
261 SY-7-4 IGF1 GH an Prolactin Receptors in Human Breast Cancer Peyrat, J.Ph.
 1996
 32 S2 p. 43-
1 p.
 article
262 SY-2-2 Imaging of DCIS for diagnosis and treatment Gilles, R.
 1996
 32 S2 p. 8-
1 p.
 article
263 SY-4-4 Immunohistochemistry as a tool for new prognostic markers Grogan, G.Mac
 1996
 32 S2 p. 25-
1 p.
 article
264 SY-3-4 Impact of local control on survival Kurtz, J.
 1996
 32 S2 p. 9-
1 p.
 article
265 SY-4-2 Invasiveness markers Roos, E.
 1996
 32 S2 p. 25-
1 p.
 article
266 SY-3-2 Local recurrences after breast conserving therapy: Therapeutical factors Cataliotti, L.
 1996
 32 S2 p. 8-9
2 p.
 article
267 SY-3-1 Local recurrences after breast conserving therapy: Tumor characteristics Holland, R.
 1996
 32 S2 p. 8-
1 p.
 article
268 SY-1-3 Loss of heterozygosity and prognosis Lidereau, Rosette
 1996
 32 S2 p. 7-
1 p.
 article
269 SY-8-4 New Bisphosphonates Coleman, R.E.
 1996
 32 S2 p. 44-
1 p.
 article
270 SY-8-1 New cytotoxic agents active in breast cancer (BC) Eisenhauer, E.A.
 1996
 32 S2 p. 43-
1 p.
 article
271 SY-8-3 New drugs other than chemotherapeutic or hormonal agents: The hope for innovative treatment strategies against breast cancer Piccart, M.J.
 1996
 32 S2 p. 44-
1 p.
 article
272 SY-8-2 New hormonal agents Paridaens, R.
 1996
 32 S2 p. 43-44
2 p.
 article
273 SY-7-2 Oestrogen receptor mutations and variant forms Dowsett, M.
 1996
 32 S2 p. 43-
1 p.
 article
274 SY-9-1 Patient's Perception Thornton, H.
 1996
 32 S2 p. 44-
1 p.
 article
275 SY-6-2 place of adjuvant chemotherapy after 50 Roché, H.
 1996
 32 S2 p. 26-
1 p.
 article
276 SY-1-4 P53 mutations and other genetic changes in invasive and intraductal breast cancer van de Vijver, M.J.
 1996
 32 S2 p. 7-
1 p.
 article
277 SY-4-1 proliferation markers in breast cancers Darro, F.
 1996
 32 S2 p. 25-
1 p.
 article
278 SY-1-1 Quality control in molecular pathology De Bortoli, Michele
 1996
 32 S2 p. 7-
1 p.
 article
279 SY-9-3 Quality of Life of Women in EORTC Trials Kiebert, G.M.
 1996
 32 S2 p. 44-
1 p.
 article
280 SY-5-3 Results of the 1995 meta analysis Gray, R.
 1996
 32 S2 p. 26-
1 p.
 article
281 SY-5-1 Risk determination for good prognosis patients Namer, M.
 1996
 32 S2 p. 25-26
2 p.
 article
282 SY-5-2 Selection of treatment Pritchard, K.I.
 1996
 32 S2 p. 26-
1 p.
 article
283 SY-6-3 skeletal problems in postmenopausal women Tubiana-Hulin, M.
 1996
 32 S2 p. 26-
1 p.
 article
284 SY-2-3 SY04 ductal carcinomas in situ: Clinical trials Julien, J.P.
 1996
 32 S2 p. 8-
1 p.
 article
285 SY-2-1 The classification of ductal carcinoma in situ of the breast Millis, R.R.
 1996
 32 S2 p. 7-8
2 p.
 article
286 SY-3-3 The need for boost doses in breast conserving therapy Bartelink, H.
 1996
 32 S2 p. 9-
1 p.
 article
287 SY-6-1 Treatment of operable breast cancer in the elderly Fentiman, I.S.
 1996
 32 S2 p. 26-
1 p.
 article
288 SY-5-4 Trials in progress and trials now needed Senn, H.J.
 1996
 32 S2 p. 26-
1 p.
 article
                             288 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands